A partnership between Dr. Reddy's Laboratories and Extrovis AG launched an authorized generic in the U.S. on August 18, 2025.
2 reports, 2 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A partnership between Dr. Reddy's Laboratories and Extrovis AG launched an authorized generic in the U.S. on August 18, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Dr. Reddy's Laboratories
Indian integrated pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireExtrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. CARAC (fluorouracil cream), 0.5% Press Release Extrovis AG and Dr. Reddy’s a
- ZacksDr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues Dr. Reddy's Laboratories Limited RDY reported first-quarter fiscal 2026 earnings of 20 cents per American Depositary Share (ADS),